Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 7/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.79 |
| ▸ | PLK4 | O00444 | 2/20 | 0.79 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.79 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.79 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.79 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.79 |
| ▸ | INSR | P06213 | 2/20 | 0.79 |
| ▸ | LCK | P06239 | 2/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | FES | P07332 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766479 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL2115189 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| Hydrochloric Acid SCHEMBL9959118 | 0.99 | KDR (0.98) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| Hydrochloric Acid SCHEMBL9959125 | 0.99 | KDR (0.98) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL29856566 | 0.93 | KDR (0.86) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL14047978 | 0.93 | KDR (0.86) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL28430885 | 0.92 | KDR (0.86) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL28430880 | 0.92 | KDR (0.86) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL13755277 | 0.92 | KDR (0.85) | KDRPRKAA1PRKAA2TLK2PDGFRB | |
| SCHEMBL31672471 | 0.92 | KDR (0.84) | KDRPRKAA1PRKAA2TLK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| EP-1419151-B1 | CHRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO)ETHYL] -5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOLE-3-YLIDENE)METHYL] -2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, PROCESSES FOR ITS PREPARATION AND COMPOSITIONS THEREOF | PHARMACIA & UPJOHN CO LLC (US) | 2014-02-26 | — | — | EP | claimed |
| US-20090074787-A1 | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer | PFIZER, INC., PFIZER PRODUCTS, INC. | 2009-03-19 | — | — | US | claimed |
| EP-1863532-A1 | ANTI-CTLA4 ANTIBODY AND INDOLINONE COMBINATION THERAPY FOR TREATMENT OF CANCER | Pfizer Products Incorporated (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006101692-A1 | ANTI-CTLA4 ANTIBODY AND INDOLINONE COMBINATION THERAPY FOR TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-20090074787-A1 | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer | PFIZER, INC., PFIZER PRODUCTS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074787-A1 | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer | PFIZER, INC., PFIZER PRODUCTS, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1863532-A1 | ANTI-CTLA4 ANTIBODY AND INDOLINONE COMBINATION THERAPY FOR TREATMENT OF CANCER | Pfizer Products Incorporated (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863532-A1 | ANTI-CTLA4 ANTIBODY AND INDOLINONE COMBINATION THERAPY FOR TREATMENT OF CANCER | Pfizer Products Incorporated (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006101692-A1 | ANTI-CTLA4 ANTIBODY AND INDOLINONE COMBINATION THERAPY FOR TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101692-A1 | ANTI-CTLA4 ANTIBODY AND INDOLINONE COMBINATION THERAPY FOR TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | KDR 3687/4885PRKAA1 3094/4885PRKAA2 3587/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | KDR 71/4885PRKAA1 1046/4885PRKAA2 1271/4885 |
| US-20090074787-A1 | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer | CD274, PDCD1, NT5M | KDR 567/4885PRKAA1 2553/4885PRKAA2 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.